Alphamab Oncology (HKG:9966)
Hong Kong
· Delayed Price · Currency is HKD 10.64
-0.29 (-2.65%)
Apr 29, 2026, 4:08 PM HKT
Alphamab Oncology Balance Sheet
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2017 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2017 |
| Cash & Equivalents | 258.82 | 1,112 | 1,086 | 1,069 | 803.31 | Upgrade
|
| Short-Term Investments | 1,092 | 459.35 | 321.25 | 247.86 | 1,128 | Upgrade
|
| Trading Asset Securities | - | - | - | 33.33 | 54.01 | Upgrade
|
| Cash & Short-Term Investments | 1,350 | 1,571 | 1,407 | 1,350 | 1,985 | Upgrade
|
| Cash Growth | -14.07% | 11.67% | 4.21% | -31.99% | -3.82% | Upgrade
|
| Accounts Receivable | 62.23 | 20.3 | 7.13 | 15.49 | 7.61 | Upgrade
|
| Other Receivables | 73.35 | 37.77 | 65.42 | 64.03 | 59.92 | Upgrade
|
| Receivables | 135.58 | 58.07 | 72.55 | 79.52 | 67.53 | Upgrade
|
| Inventory | 107.88 | 81.81 | 78.75 | 64.64 | 57.91 | Upgrade
|
| Other Current Assets | - | - | - | - | 5.63 | Upgrade
|
| Total Current Assets | 1,594 | 1,711 | 1,559 | 1,495 | 2,117 | Upgrade
|
| Property, Plant & Equipment | 496.32 | 524.01 | 576.95 | 619.74 | 530.52 | Upgrade
|
| Long-Term Accounts Receivable | 4.5 | - | - | - | - | Upgrade
|
| Other Long-Term Assets | 2.46 | 6.4 | 1.63 | 3.26 | 58.02 | Upgrade
|
| Total Assets | 2,097 | 2,242 | 2,137 | 2,118 | 2,705 | Upgrade
|
| Accounts Payable | 70.56 | 42.29 | 31.54 | 17.63 | 28.48 | Upgrade
|
| Accrued Expenses | 146.8 | 118.93 | 119.89 | 135.36 | 109.04 | Upgrade
|
| Current Portion of Long-Term Debt | 33.48 | 52.26 | 75 | 175 | 449.99 | Upgrade
|
| Current Portion of Leases | 2.18 | 2.44 | 5.5 | 15.11 | 13.82 | Upgrade
|
| Current Unearned Revenue | 9.68 | 15.48 | 6.86 | 13.07 | 6.38 | Upgrade
|
| Other Current Liabilities | 18.15 | 22.64 | 28.05 | 28.74 | 29.55 | Upgrade
|
| Total Current Liabilities | 280.85 | 254.04 | 266.84 | 384.91 | 637.26 | Upgrade
|
| Long-Term Debt | 85.22 | 129.98 | 175 | 150 | 153.83 | Upgrade
|
| Long-Term Leases | 2.1 | 1.27 | 1.58 | 5.28 | 19.63 | Upgrade
|
| Long-Term Unearned Revenue | 18.01 | 24.57 | 21.58 | 19.67 | 24.09 | Upgrade
|
| Total Liabilities | 386.17 | 409.87 | 465 | 559.86 | 834.8 | Upgrade
|
| Common Stock | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | Upgrade
|
| Additional Paid-In Capital | - | 4,055 | 4,053 | 3,726 | 3,717 | Upgrade
|
| Retained Earnings | - | -2,177 | -2,343 | -2,132 | -1,807 | Upgrade
|
| Treasury Stock | -37.12 | -9.19 | - | - | - | Upgrade
|
| Comprehensive Income & Other | 1,748 | -37.43 | -37.64 | -35.85 | -39.84 | Upgrade
|
| Total Common Equity | 1,711 | 1,832 | 1,672 | 1,558 | 1,870 | Upgrade
|
| Shareholders' Equity | 1,711 | 1,832 | 1,672 | 1,558 | 1,870 | Upgrade
|
| Total Liabilities & Equity | 2,097 | 2,242 | 2,137 | 2,118 | 2,705 | Upgrade
|
| Total Debt | 122.98 | 185.96 | 257.08 | 345.39 | 637.27 | Upgrade
|
| Net Cash (Debt) | 1,227 | 1,386 | 1,150 | 1,005 | 1,348 | Upgrade
|
| Net Cash Growth | -11.42% | 20.46% | 14.45% | -25.46% | -26.78% | Upgrade
|
| Net Cash Per Share | 1.28 | 1.41 | 1.20 | 1.07 | 1.44 | Upgrade
|
| Filing Date Shares Outstanding | 968.57 | 961.97 | 964.84 | 939.72 | 934.94 | Upgrade
|
| Total Common Shares Outstanding | 968.57 | 961.97 | 964.84 | 939.72 | 934.94 | Upgrade
|
| Working Capital | 1,313 | 1,457 | 1,292 | 1,110 | 1,479 | Upgrade
|
| Book Value Per Share | 1.77 | 1.90 | 1.73 | 1.66 | 2.00 | Upgrade
|
| Tangible Book Value | 1,711 | 1,832 | 1,672 | 1,558 | 1,870 | Upgrade
|
| Tangible Book Value Per Share | 1.77 | 1.90 | 1.73 | 1.66 | 2.00 | Upgrade
|
| Buildings | 298.2 | 298.2 | 303.51 | 285.28 | 227.4 | Upgrade
|
| Machinery | 430.48 | 397.62 | 384.82 | 286.3 | 152.46 | Upgrade
|
| Construction In Progress | 1.14 | 7.41 | 0.89 | 90.83 | 143.08 | Upgrade
|
| Leasehold Improvements | 12.53 | 6.26 | 6.26 | 6.75 | 1.9 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.